Arvinas (ARVN)

• Market cap: $1.23B
• 1 day: 1.94%
• 5 days: -0.17%
• 1 month: -5.84%
• 3 months: -35.32%
• 6 months: -33.96%
• Year to date: -5.29%
• 1 year: -54.67%
• 5 years: -64.17%
• 10 years: 11.46%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 445

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

11% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 64

0% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 27

0% less funds holding

Funds holding: 205 [Q2] → 204 (-1) [Q3]

0.82% less ownership

Funds ownership: 107.65% [Q2] → 106.84% (-0.82%) [Q3]

8% less capital invested

Capital invested by funds: $1.96B [Q2] → $1.81B (-$154M) [Q3]

19% less call options, than puts

Call options by funds: $5.79M | Put options by funds: $7.15M

29% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 5 (-2) [Q3]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $40 124% upside
• Avg. target: $68 277% upside
• High target: $88 392% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 41% 1-year accuracy 45 / 109 met price target	386% upside $87	Buy Reiterated	11 Dec 2024
BMO Capital Etzer Darout 0% 1-year accuracy 0 / 5 met price target	392% upside $88	Outperform Maintained	20 Nov 2024
Stephens & Co. Sudan Loganathan 0 / 0 met price target	207% upside $55	Overweight Initiated	18 Nov 2024
Oppenheimer Matthew Biegler 0 / 0 met price target	124% upside $40	Outperform Maintained	31 Oct 2024